Substantial progress has recently been made in optimizing the management of cancer patients, resulting in major gains in survival and quality of life. Much of this progress has resulted from the serial testing of promising treatment strategies, typically using prospective randomized controlled trials to compare outcomes achieved with the new approach versus the current standard(s) of care. However, there is an ever-expanding list of important questions that are difficult to investigate, particularly with respect to determining the optimal sequencing and combination of proven active agents. With the rapidly growing list of clinical, pathologic and molecular characteristics that promise to predict treatment benefit and/or risk for defined patient subsets, many new questions regarding how best to personalize our approach to treatment selection are emerging. These questions can be investigated in the context of registry-based randomized clinical trials. Recently, the potential of registry-based randomized clinical trials was demonstrated in cardiology, highlighting the ability to rapidly recruit large numbers of patients to a trial addressing an important clinical question, with minimal cost and high external validity. In this review, we discuss the challenges and limitations of conventional clinical trials in multidisciplinary cancer care, describe the potential advantages of registry-based randomized trials, and highlight several registry-based oncology studies that are already underway to demonstrate the feasibility of this approach.
INTRODUCTION
Randomized controlled trials (RCTs) serve as a tool for comparing existing treatments, as well as evaluating the efficacy of new therapies.
These can be conducted in a broad patient population or in a specific subset of patients. Fundamental to the success of RCTs are the inclusion and exclusion criteria that impact patient enrolment, stratification according to known prognostic and predictive factors and the use of randomization. Ultimately, the aim is that any differences in outcome can be presumed to be due to the differential effects of the management strategies being compared. In an ideal world, each RCT would recruit a patient sample that is truly representative of the general population of cancer patients, thus maximizing the external validity of the results. However, the majority of conventional RCTs have highly selective inclusion and exclusion criteria, which can limit their true generalizability.
In this article, we aim to describe the challenges and limitations of RCTs in cancer medicine and the opportunity to bridge the gap between RCTs and real-world clinical practice using prospective, registry-based randomized clinical trials (RRCTs). We discuss how this approach can improve some of the prohibitive aspects of conducting an RCT and explore the drawbacks of using this study design. Finally, we introduce RRCTs that we are currently undertaking to demonstrate their feasibility and potential to accelerate progress in optimizing patient treatment and outcomes in medical oncology.
STRENGTHS AND LIMITATIONS OF CONVENTIONAL RCTS
Randomized controlled trials (RCTs) form the evidentiary backbone of clinical practice guidelines and represent the gold standard in the clinical research paradigm. 1, 2 RCTs are quantitative, comparative, controlled clinical experiments. The strength of the RCT rests on high internal validity, relying on the combination of stratification and randomization to ensure that the only systematic difference between two treatment arms is the patients' exposure to the intervention of interest. 3 Stratification can be applied to eliminate confounding by known strong predictive factors. When properly executed, stratification guarantees perfect balance between treatment groups on the characteristics included in the study; however, it is limited by sample size: it is impossible to have more strata than observations. As such, it is impossible to achieve perfect balance on all characteristics that are potentially relevant. Instead, randomization is used to minimize the imbalance on all remaining characteristics of patients, measured or unmeasured, causally related or unrelated to the outcome of interest. 4 Furthermore, RCTs are controlled, prospective trials and these properties help establish causality as opposed to mere correlation or reverse causality.
However, RCTs can be subject to extrapolation bias that limit their impact on the care of patients in routine clinical practice. Often the selective nature of inclusion criteria applied to clinical trials can restrict participation to a subset of patients, 5 typically those that are relatively young and fit and/or with minimal comorbidities. In contrast, a large proportion of patients presenting for treatment advice in the real world are frail, of advanced age and/or have multiple comorbidities.
Determining the relevance and generalizability of the results achieved in RCTs conducted in patients with narrow selection criteria and strict protocols is a continuous challenge for clinicians. 6, 7 Although generalization is nontrivial even in optimal circumstances, the reporting of selection criteria for RCTs is often incomplete and this further obstructs proper interpretation of the results. 8 A study examining the reporting of selection criteria from 52 clinical trial protocols and the resulting publications found discrepancies in all trials assessed.
Of the 1,248 eligibility criteria pre-specified in the protocols, 479 were missing and 163 were modified in the final publication. Of concern, the vast majority of missing eligibility criteria (96%) and the majority of modified eligibility criteria (54%) suggested that broader populations than initially specified were included in the studies. 9 Modified, incomplete or inadequate reporting of eligibility criteria can drastically alter the context and applicability of trial results.
Another challenge associated with conventional clinical trials is the escalating cost of conducting RCTs, limiting the number of potential studies that can be undertaken in an increasingly resource-strained environment. Furthermore, the high cost of purchasing newer drugs prevent many of them from being tested in novel settings, such as a different patient group, a different disease or disease subset or a different line of therapy. Exploring these new frontiers relies on substantial funding support being provided by the pharmaceutical industry in the form of free drug supply. Increasingly, tumor types are being further sub-categorized according to clinical, pathologic, molecular or prior treatment characteristics rather than simply the tumor site of origin. For example, studies of patients with metastatic colorectal cancer (mCRC) may focus on a clinical subset (e.g. resectable liver metastases), 10 a molecular subset (e.g. KRAS wild-type) 11 or mandate a prior number of therapy(ies). 12 Subclassification can limit the number of available patients that can be recruited and by extension, the feasibility of individual sites to participate in new trials. Where the focus is on even more uncommon subsets, such as BRAF-mutated mCRC (8-12% of patients), 13, 14 HER2-expressing mCRC (5%) 15 or mismatch repair deficient mCRC (5%) 14 very few sites can contribute significant numbers of patients. Given the time, effort and costs associated with opening a trial at each site, it may not be feasible for the investigator or the sponsor to open a study that is predicted to recruit only one or two patients over the projected study period.
By this mechanism, centers contributing patients to clinical trials are also increasingly selected, with the centers recruiting the majority of patients likely to have the largest patient volumes and an interest or expertise in the disease type being studied. 16 Treatment outcomes achieved at these major clinical centers may possibly be significantly different to those achieved with the same approach at a smaller, nonspecialist center. Factors contributing to this potential discrepancy include the treatment being provided by highly expert subspecialist clinicians who are supported by expert trial nurses, pharmacists and radiologists; and the patient population being fit and motivated to travel to the center to participate in a clinical trial that offers access to a promising new therapy. 17 Consequently, for many reasons the gains achieved in clinical trials do not necessarily translate to the broader clinical population across the spectrum of health care systems. 18 The outcomes of a drug given frequently at a major treatment center are conceivably quite different to the same drug being delivered infrequently at smaller centers. 19 With a growing number of treatment options and potential biomarkers for cancer patients, there is a rapidly expanding number of unanswered questions related to the optimal combining or sequencing of treatment options and how best to tailor this for each individual patient and their circumstances. New approaches to advancing knowledge are needed, in particular approaches that deliver estimates that are unbiased and can readily be used to impact practice without the need to extrapolate to a significantly different patient population.
STRENGTHS AND LIMITATIONS OF CLINICAL REGISTRIES TO ADVANCE THERAPY KNOWLEDGE
A clinical registry is defined as an organized system that uses observational study methods to systematically collect uniform data to evaluate specified outcomes for a population defined by a particular disease. 20 The Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) is one of the best-known efforts to collect a standard dataset on consecutive cancer patients. 21 Data collection for the SEER program began in 1973 and initially included data from seven geographic areas in the United States. 22 Later this effort was expanded to include data collection across 20 geographic areas representing approximately 28% of the US population. SEER collects information on patient demographics, tumor characteristics, including primary tumor location and extent of disease, and the use of cancer-directed surgery, radiation therapy, systemic therapy and patient survival. 21 The main limitation of SEER data is not its validity but rather the depth of clinical information; 23 in SEER, treatment data are only collected for the first course of treatment, 24 which can limit analysis of treatment outcomes across different centers. Linkage of SEER data to Medicare claims for health care services allows a more comprehensive examination of treatment information, but SEER-Medicare only captures data on patients aged 65 years and older, 25 limiting its generalizability. Further, the SEER data on metastatic tumors are often inadequate (this data are only captured well if the tumor is metastatic at diagnosis); and SEER does not include detailed data on comorbidities, potentially important confounders of treatment responses and outcomes. 22, 23 The SEER program highlights some of the advantages and disadvantages associated with observational research based on analysis of clinical registry data. Broad inclusion criteria increase the probability that patient numbers are sufficiently large to explore outcomes in various subpopulations of interest, including those that are underrepresented in RCTs. Registries such as SEER can provide data on the benefit and safety of new therapies once they are adopted in the routine clinical setting. 26 However, in these analyses for efficacy and/or safety, therapy selection bias is always a confounding factor as almost inevitably it is the fitter patients with a better prognosis and potentially higher treatment tolerance that are more likely to receive the intervention, 27 and such patients have improved outcomes independent of treatment effect. Although some of this can potentially be accounted for, for example in a stratified analysis, using propensity scores or adjustment in multiple regression, in the absence of randomization it is not possible to be confident that observed differences are truly the result of treatment impact. It is impossible to adjust for characteristics that were not measured. Although all studies are limited to observed data, available registry data are limited by design choices that may not have been optimal for the research question. Lack of data availability is not limited to diagnostic or prognostic factors; efficacy analyses may also be influenced by nonstandardized endpoints or endpoints that are difficult to evaluate retrospectively, although reliable outcome data can be achieved for hard endpoints such as overall survival. Finally, data quality is a common and legitimate concern for registry-based research, particularly where data are collected retrospectively or for data points that may be poorly documented in the clinical notes, such as performance status, comorbidity, family history or patient preferences. Reporting specifications and standards may also be modified over time or differ between regions, which may lead to differences in quality and incompatible categorisations.
Despite statistical advances 28 because they lack the credibility associated with pre-registration and randomization. 29 The "intellectual trap" described by Lauer and D'Agostino 30 between randomized trials that lack external validity (generalizability) and observational studies that lack internal validity, owing to unmeasured confounders, can be avoided using a randomized registry-based approach (Table 1) . and are yet to be explored as an alternative to conventional randomized studies in oncology. By combining the major strengths of a conventional RCT, namely patient stratification and randomization, important questions could be reliably addressed using RRCTs with greater ease and at significantly lower cost. Rapid patient recruitment is typically achieved by consecutive enrolment using generous eligibility criteria, which also enhances the generalizability of results due to inclusion of a real-world population. 5, 28 Essentially replacing the case report form (CRF) used for a conventional RCT is the registry database, which captures the key data relevant to the patient group, the treatment administered and the outcome of interest. Typically, the registry database will have far less data for each patient than is captured for a conventional RCT, but where the treatments are with standard agents or common treatment combinations with well described adverse events, the focus of the RRCT can The study protocol was developed based on the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), which formed the platform for randomization. 33 SCAAR is one of four registries that form part of Sweden's national online cardiac registry: the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). 34, 35 Using an established online registry as the basis for randomization, case record form data collection and followup made the trial economically and administratively feasible. 36 A total of 7,244 patients, representing 60% of all STEMI patients referred for PCI in Sweden and Iceland during the study period, were randomized to receive PCI with or without thrombus aspiration. The study found no statistically significant difference in mortality at 30 days between the two groups. The study was completed in less than three years at an estimated cost of US$50 per randomized patient, a > 90% cost saving compared to a similar conventional RCT. 1, 37 Despite the benefits we have highlighted and the suitability of RRCTs to answer questions about effectiveness of treatments in realworld practice, challenges exist and care needs to be taken when determining if a registry-based approach is suitable (Table 1) . A search of the clinicaltrial.gov website 38 identified at least nine ongoing RCTs implementing a registry-based approach (Table 3) ; notably none of these trials are enrolling patients with cancer.
THE POTENTIAL OF REGISTRY-BASED RCTS IN MEDICAL ONCOLOGY
In oncology practice, it is common to have multiple treatment options to select from, often with no clearly superior approach. Frequently this is because head-to-head RCTs have not been conducted successfully or Spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction, SPIRRIT-HFPEF
TA B L E 3 Active registry-based randomized clinical trials

Not yet recruiting
Heart failure with preserved ejection fraction Sweden NCT02901184 December 2017
The effect of higher protein dosing in critically ill patients: a multicenter registry-based randomized trial
Critical illness, malnutrition Canada NCT03160547 January 2018 
Metastatic colorectal cancer: ALT-TRACC
ALT-TRACC is an RRCT randomizing patients with treatment-naïve mCRC to alternating two cycles of oxaliplatin and irinotecan doublet chemotherapy versus standard continuous doublet chemotherapy.
The hypothesis is that using alternating schedules of oxaliplatin and irinotecan doublets might increase efficacy by delaying the emer- 
Glioblastoma: EX-TEM
EX-TEM is an RRCT where recently diagnosed glioblastoma patients will be randomized to receive the standard 6 months of 46 The justification for a definitive randomized study is that several small retrospective studies and limited random- Recently, this study has been endorsed by the Cooperative Trials
TA B L E 5 Key features of ALT-TRACC, EX-TEM and PAN PAL
Group for Neuro-Oncology (COGNO), with a commitment to support this study at a large number of centers across Australia.
Pancreatic cancer: PAN-PAL
PAN-PAL will randomize patients with recently diagnosed metastatic pancreatic cancer to early palliative care integrated with standard oncologic care or standard oncologic care alone, with palliative care referral in the standard arm at clinician discretion. Previous studies have indicated that late referrals to palliative care compromise the meaningful effect that these services can provide to quality of life and end-of-life care for patients with metastatic disease. 50 Along with this, however, is the seminal RCT in metastatic non-small cell lung cancer that demonstrated that early integration of palliative care resulted in clinically meaningful and statistically significant gains in overall survival. 51 In the absence of an explanation for this survival gain, the clinical community remains uncertain about the survival impact of early palliative care referral, however it is clearly a study that is worth repeating, albeit in a different poor prognosis tumour type. A fur-
ther RCT in pancreatic cancer demonstrated that early palliative care improved quality of life and had a significant positive impact on indicators of end-of-life treatment aggressiveness, however no difference in survival outcomes was found. 52 This study was arguably limited by treating oncologists in the control arm being trained in palliative care delivery, thereby reducing the impact of the interventional arm. Furthermore, the palliative care intervention involved a single physician expert only. PAN-PAL will evaluate this intervention in a multicenter fashion, utilizing an RRCT platform.
Each of these registry RCTs will be powered to show a difference in the same hard endpoint, that is overall survival, and linkage with the cancer registry and national death index will be undertaken to ensure accurate survival data are obtained.
CONCLUSIONS
Registry-based RCTs can provide a timely and cost-effective solution to answering clinical questions, which could be practice changing while bridging the gap between RCTs and observational studies, including phase IV clinical trials. Registry-based randomized trials can reduce costs and simplify trial conduct while achieving both high internal and external validity. However, they rely on the availability of extensive, accessible, high-quality registries and appropriate methods for the randomization for each trial question. We have identified several registries which provide a platform for oncology data collection, randomization and follow-up. These registries and the proposed registry RCTs provide a unique and significant opportunity for a new approach to clinical research in oncology. 
